# Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

*PRI Rank #12 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-12*

| Field | Value |
| --- | --- |
| Rank | #12 |
| 18m citations | 36 |
| Journal | The Lancet Oncology |
| Year | 2024 |
| DOI | 10.1016/s1470-2045(24)00373-5 |
| Corresponding authors | Mafalda Oliveira |
| Institution | Vall d'Hebron University Hospital, Spain |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1016/s1470-2045(24)00373-5](https://doi.org/10.1016/s1470-2045(24)00373-5)

## Topics

capivasertib · fulvestrant · hormone receptor-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · CAPItello-291 · patient-reported outcomes · phase 3 trial · AKT inhibitor · endocrine therapy combination · quality of life assessment · Randomized double-blind placebo-controlled trial

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```